CARB-X is awarding up to US$2.91 million to Evotec SE, a drug discovery and development company in Germany, to develop a new class of antibiotics to treat infections caused by deadly multidrug-resistant Gram-positive and Gram-negative bacteria.
Britain and India are expanding their existing scientific research collaboration with five new projects to tackle anti-microbial resistance (AMR) that could lead to important advances in the global fight against antibiotic-resistant bacteria and genes. The five projects are planned to start in September 2020. The UK is contributing £4 million from the UK Research and Innovation Fund for International Collaboration, and India is matching this with its own resources (£8 million in total).
Dutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.
The Biomedical Advanced Research and Development Authority (BARDA) annual Industry Day 2019 conference on US government medical countermeasures is planned October 2019.
Although new antibiotics are very much needed, they will only be most effective if they’re used sparingly — for the most critical of cases. This presents serious economic challenges to developing antibiotics.
The development and ultimate approval of tecovirimat for the antiviral treatment of smallpox, a disease that has been eradicated from the world for nearly 40 years, required a unique regulatory approach based on the US Food and Drug Administration's Animal Rule.
This year’s event will gather leaders from pharmaceutical companies, academia and the wider scientific community together with regulatory agencies and public-private partnerships, to discuss the growing threat of antibiotic resistance.
Using computer modelling, researchers were able to identify new drugs by building a reliable replica of the bacterial protein and then working out what the best orientation is for the drug to fit in the bacterial protein.
The aim of the conference is to harness cross-disciplinary and cross-disease learning to accelerate drug discovery and reduce drug candidate attrition rates for infectious diseases affecting low and middle income countries. Conference attendees will take home new ideas and technologies which have been demonstrated to work; applying them to diseases where challenges to drug discovery are hampering progress.
Accepting that antibiotics are infrastructure would change our relationship to the drugs, forcing us to recognize that medicine requires long-term planning.